ArticleAnnals of hematology2025
Zanubrutinib plus salvage chemotherapy in patients with refractory/relapsed diffuse large B-cell lymphoma non-candidate for autologous stem cell transplantation: A retrospective study.
Article in Annals of hematology, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
1 citing paper in PubMed.
- Real-world effectiveness of zanubrutinib plus salvage chemotherapy in relapsed or refractory double-expressor DLBCL.Annals of hematology · 2026Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
6 authors.
Funding
Abstract
Salvage chemotherapy followed by autologous stem cell transplantation (auto-SCT) is effective for relapsed or refractory DLBCL (R/R DLBCL), but many patients are ineligible due to age, comorbidities, tolerance, economy and other factors. Zanubrutinib, a selective Bruton's tyrosine kinase inhibitor, has modest antitumor activity in R/R DLBCL. This study aimed to evaluate the efficacy and safety of zanubrutinib plus salvage chemotherapy in transplant-ineligible patients with R/R non-GCB DLBCL. We retrospectively reviewed patients with R/R non-GCB DLBCL treated with zanubrutinib combined with BR (bendamustine + rituximab; ZBR) or R2 (lenalidomide + rituximab; ZR2) between January 2019 and July 2023. A total of 49 patients were enrolled with a median age of 60 years. The best objective response rate (ORR) was 57.1% with a complete response (CR) rate of 12.2% in the entire cohort. 19 patients were treated with ZBR and 30 patients were treated with ZR2. The ORR of ZBR and ZR2 cohort was 63.2% and 53.3% respectively. With a median follow-up duration of 22 months, the median progression free survival (PFS) was 6.0 months, and overall survival (OS) was 21.0 months. Patients in CD79B ± MYD88 mutated subgroup had a significantly higher ORR (86.7% v 44.1%, P = 0.006) and longer PFS (8.1 v 4.9 months, P = 0.009) compared to those in CD79B ± MYD88 non-mutated subgroup. A significant PFS and OS benefit was observed in the patients who responded to the treatment. The most common grade 3/4 adverse events were neutropenia (46. 9%) and thrombocytopenia (44.9%). Zanubrutinib combined with BR or R2 showed promising efficacy and manageable toxicity, which may be a potential treatment option for patients with transplant-ineligible R/R non-GCB DLBCL.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.